RxDoctor Payments DataLook up a doctor →

Dawn Ngo, PA

Physician Assistant · American Fork, UTNPI 1194805978

Payments from drug & device makers

$11,199in general payments, 2019–2025

Across 691 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$773
  • Nestle Healthcare Nutrition Inc.$396
  • Pfizer$380
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$10,90197%
  • Education$2983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,199 in reported general payments places this provider in the 95th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$33,309
Medicare patients
171
Services billed
585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab25$683,041
Humira(Cf) PenAdalimumab19$284,642
Cimzia (2 Pack)Certolizumab Pegol12$159,393
LinzessLinaclotide32$33,984
MovantikNaloxegol Oxalate20$14,794
Omeprazole228$7,611
Mesalamine11$7,045
Balsalazide Disodium12$3,563
Ursodiol17$3,392
Lubiprostone29$2,858
Pantoprazole Sodium103$2,422
Famotidine92$2,012
Dicyclomine Hcl63$1,329
Sucralfate29$1,328
Azathioprine12$1,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,228$683,04125 claims
AbbVieLinzess$4,241$33,98432 claims
Redhill Biopharma Inc.Movantik$264$14,79420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in American Fork

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →